GSK (XTER:GS71) Cyclically Adjusted Revenue per Share: €10.27 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:GS71 GSK PLC XTER:GS71
76 GF Score
Price €22.30
GF Value €19.04
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GSK Cyclically Adjusted Revenue per Share?

GSK XTER:GS71 -0.54% 76 Cyclically Adjusted Revenue per Share is €10.27 as of Mar. 2026. GuruFocus rates XTER:GS71 with a GF Score™ of 76/100 and a GF Value™ of €19.04 (Modestly Overvalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

GSK's adjusted revenue per share for the three months ended in Mar. 2026 was €2.160. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €10.27 for the trailing ten years ended in Mar. 2026.

During the past 12 months, GSK's average Cyclically Adjusted Revenue Growth Rate was 2.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 2.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 2.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of GSK was 9.10% per year. The lowest was 0.60% per year. And the median was 4.20% per year.

As of today (2026-07-24), GSK's current stock price is €22.30. GSK's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €10.27. GSK's Cyclically Adjusted PS Ratio of today is 2.17.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GSK was 2.50. The lowest was 1.48. And the median was 2.01.


GSK  (XTER:GS71) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

GSK's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=22.30/10.27
=2.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GSK was 2.50. The lowest was 1.48. And the median was 2.01.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


GSK Cyclically Adjusted Revenue per Share Related Terms


GSK Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for GSK's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK Cyclically Adjusted Revenue per Share Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.39 9.41 9.70 10.53 10.30

GSK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.52 10.40 10.23 10.30 10.27

XTER:GS71 vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted PS Ratio falls into.


XTER:GS71
76GF Score
GSK PLC XTER:GS71
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GSK's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.16/140.8000*140.8000
=2.160

Current CPI (Mar. 2026) = 140.8000.

GSK Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 2.124 101.000 2.961
201609 2.252 101.500 3.124
201612 2.264 102.200 3.119
201703 2.166 102.700 2.970
201706 2.134 103.500 2.903
201709 2.222 104.300 3.000
201712 2.176 105.000 2.918
201803 2.068 105.100 2.770
201806 2.097 105.900 2.788
201809 2.279 106.600 3.010
201812 2.287 107.100 3.007
201903 2.243 107.000 2.952
201906 2.194 107.900 2.863
201909 2.633 108.400 3.420
201912 2.593 108.500 3.365
202003 2.540 108.600 3.293
202006 2.109 108.800 2.729
202009 2.358 109.200 3.040
202012 -0.275 109.400 -0.354
202103 2.145 109.700 2.753
202106 1.683 111.400 2.127
202109 1.909 112.400 2.391
202112 2.051 114.700 2.518
202203 2.115 116.500 2.556
202206 1.589 120.500 1.857
202209 2.191 122.300 2.522
202212 2.074 125.300 2.331
202303 1.929 126.800 2.142
202306 2.044 129.400 2.224
202309 2.298 130.100 2.487
202312 2.269 130.500 2.448
202403 2.093 131.600 2.239
202406 2.261 133.000 2.394
202409 2.306 133.500 2.432
202412 2.357 135.100 2.456
202503 2.171 136.100 2.246
202506 2.286 138.400 2.326
202509 2.399 138.900 2.432
202512 2.414 139.900 2.430
202603 2.160 140.800 2.160

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €10.27 mean?
GSK (XTER:GS71) has a Cyclically Adjusted Revenue per Share of €10.27 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on GSK and its competitors.
Is GSK's Cyclically Adjusted Revenue per Share too high?
GSK's current Cyclically Adjusted Revenue per Share is €10.27. Overall, GSK has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
GSK's Cyclically Adjusted Revenue per Share of €10.27 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on GSK and its competitors. GSK's current Cyclically Adjusted Revenue per Share is €10.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (XTER:GS71) is currently considered Modestly Overvalued. The stock's GF Value™ is €19.04, compared to a current price of €22.30 — trading 17.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €10.27. GSK's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For GSK (XTER:GS71), the current Cyclically Adjusted Revenue per Share is €10.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (XTER:GS71) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of €22.30 is trading 17.1% above its estimated GF Value™ of €19.04. GuruFocus considers GSK to be Modestly Overvalued.

Key valuation signals for XTER:GS71:

  • Cyclically Adjusted Revenue per Share: €10.27
  • GF Value™: €19.04 vs. price of €22.30 (17.1% above fair value)
  • GF Score™: 76/100 with 1 warning sign

No single metric tells the full story. See the XTER:GS71 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
76GF Score

Get the complete analysis for XTER:GS71

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.30
Price
€19.04
GF Value